Form 8-K bluebird bio, Inc. For: Aug 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
bluebird bio (BLUE) PT Lowered to $19 at Morgan Stanley
August 11, 2021 8:26 AM EDTMorgan Stanley analyst Matthew Harrison lowered the price target on bluebird bio (NASDAQ: BLUE) to $19.00 (from $35.00) while maintaining a Equalweight rating.
... MoreGoldman Sachs Downgrades bluebird bio (BLUE) to Neutral
August 10, 2021 6:56 AM EDTGoldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Buy to Neutral with a price target of $23.00 (from $63.00).
The analyst comments "We downgrade BLUE from Buy to Neutral and lower our 12-month PT to $23 from $63. First, we note the newly announced clinical hold for gene therapy Lenti-D in cerebral adrenoleukodystrophy (CALD) due to a Suspected Unexpected Serious Adverse... More
bluebird bio (BLUE) PT Lowered to $18 at Stifel
August 9, 2021 1:56 PM EDTStifel analyst Benjamin J. Burnett lowered the price target on bluebird bio (NASDAQ: BLUE) to $18.00 (from $31.00) while maintaining a Hold rating.
The analyst commented, "We remain Hold rated on BLUE following two negative updates: (1) a patient treated with Lenti-D (Cerebral Adrenoleukodystrophy) developed... More
